12 months of anticoagulation improves outcomes in cancer patients with minor blood clots
Twelve months of edoxaban is superior to three months for the reduction of thrombotic events…
Twelve months of edoxaban is superior to three months for the reduction of thrombotic events…
Genetic testing could help identify breast cancer patients with high risk of experiencing venous thromboembolism…